Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis (AKTSS)

Study point of contact

Anurag Agrawal, MD
5104283539
[email protected]
Bryan Cooper-Sood, MD
5104283888
[email protected]

Locations

1 United States site

Age

8 to 25 Years

Phase

Phase 2

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

About the study

Acute vaso-occlusive episodes (VOEs) in sickle cell disease (SCD) are primarily managed with
opioids. Tolerance and hyperalgesia to opioids develops due to N-methyl-D-aspartate
(NMDA)-receptor mediated activation of the nociceptive system, and as a receptor antagonist,
ketamine mitigates this. Intravenous (IV) ketamine has demonstrated efficacy in reducing
post-operative, chronic, and cancer-related pain in pediatrics, as well as in reducing time
to pain control in the emergency department (ED) in adults. Limited studies suggest efficacy
in adult opioid-refractory SCD patients. This study is investigating the safety and
tolerability of adjuvant low-dose IV ketamine bolus for pediatric SCD VOE in the ED, as well
as its efficacy in improving pain control and reducing hospitalization.

participation requirements

– All English-speaking, sickle cell patients who receive their care at UCSFBCHO in the
Department of Hematology who are 8-to-25-years-old presenting to the emergency
department for VOC will be asked to enroll.

participation restrictions

– Prior adverse reaction to ketamine.

– Patients will be asked during the consent process if they have ever received ketamine,
and if so, if they had any serious adverse reaction, such as difficulty breathing,
dysphoria, hallucinations, or allergic reaction. If they have, ketamine will not be
given to these patients.

– Patients who have received ketamine and experienced nausea or vomiting will be asked
if they wish to receive the medication. If they do not, they will not receive
ketamine.

Locations

  • Oakland, California, United States, UCSF Benioff Children's Hospital and Research Center Oakland, 94609 [Recruiting]